159 related articles for article (PubMed ID: 35113189)
1. Bullying in clinical high risk for psychosis participants from the NAPLS-3 cohort.
Braun A; Liu L; Bearden CE; Cadenhead KS; Cornblatt BA; Keshavan M; Mathalon DH; McGlashan TH; Perkins DO; Seidman LJ; Stone W; Tsuang MT; Walker EF; Woods SW; Cannon TD; Addington J
Soc Psychiatry Psychiatr Epidemiol; 2022 Jul; 57(7):1379-1388. PubMed ID: 35113189
[TBL] [Abstract][Full Text] [Related]
2. Longitudinal impact of trauma in the North American Prodrome Longitudinal Study-3.
Farris MS; Braun A; Liu L; Bearden CE; Cadenhead KS; Cornblatt BA; Keshavan M; Mathalon DH; McGlashan TH; Perkins DO; Stone WS; Tsuang MT; Walker EF; Woods SW; Cannon TD; Addington J
Early Interv Psychiatry; 2022 Nov; 16(11):1211-1216. PubMed ID: 35152553
[TBL] [Abstract][Full Text] [Related]
3. Differential expression of haptoglobin in individuals at clinical high risk of psychosis and its association with global functioning and clinical symptoms.
Healy C; Byrne J; Raj Suasi S; Föcking M; Mongan D; Kodosaki E; Heurich M; Cagney G; Wynne K; Bearden CE; Woods SW; Cornblatt B; Mathalon D; Stone W; Cannon TD; Addington J; Cadenhead KS; Perkins D; Jeffries C; Cotter D
Brain Behav Immun; 2024 Mar; 117():175-180. PubMed ID: 38219978
[TBL] [Abstract][Full Text] [Related]
4. Prospective study of cannabis use in adolescents at clinical high risk for psychosis: impact on conversion to psychosis and functional outcome.
Auther AM; McLaughlin D; Carrión RE; Nagachandran P; Correll CU; Cornblatt BA
Psychol Med; 2012 Dec; 42(12):2485-97. PubMed ID: 22716931
[TBL] [Abstract][Full Text] [Related]
5. Toward Generalizable and Transdiagnostic Tools for Psychosis Prediction: An Independent Validation and Improvement of the NAPLS-2 Risk Calculator in the Multisite PRONIA Cohort.
Koutsouleris N; Worthington M; Dwyer DB; Kambeitz-Ilankovic L; Sanfelici R; Fusar-Poli P; Rosen M; Ruhrmann S; Anticevic A; Addington J; Perkins DO; Bearden CE; Cornblatt BA; Cadenhead KS; Mathalon DH; McGlashan T; Seidman L; Tsuang M; Walker EF; Woods SW; Falkai P; Lencer R; Bertolino A; Kambeitz J; Schultze-Lutter F; Meisenzahl E; Salokangas RKR; Hietala J; Brambilla P; Upthegrove R; Borgwardt S; Wood S; Gur RE; McGuire P; Cannon TD
Biol Psychiatry; 2021 Nov; 90(9):632-642. PubMed ID: 34482951
[TBL] [Abstract][Full Text] [Related]
6. Short-term functional outcome in psychotic patients: results of the Turku early psychosis study (TEPS).
Salokangas RKR; From T; Ilonen T; Luutonen S; Heinimaa M; Armio RL; Laurikainen H; Walta M; Paju J; Toivonen A; Jalo P; Tuominen L; Hietala J
BMC Psychiatry; 2021 Dec; 21(1):602. PubMed ID: 34856968
[TBL] [Abstract][Full Text] [Related]
7. Recovery from an at-risk state: clinical and functional outcomes of putatively prodromal youth who do not develop psychosis.
Schlosser DA; Jacobson S; Chen Q; Sugar CA; Niendam TA; Li G; Bearden CE; Cannon TD
Schizophr Bull; 2012 Nov; 38(6):1225-33. PubMed ID: 21825282
[TBL] [Abstract][Full Text] [Related]
8. Duration of Untreated Prodromal Psychosis and Cognitive Impairments.
Zhang T; Cui H; Wei Y; Tang X; Xu L; Hu Y; Tang Y; Liu H; Wang Z; Chen T; Li C; Wang J
JAMA Netw Open; 2024 Jan; 7(1):e2353426. PubMed ID: 38277145
[TBL] [Abstract][Full Text] [Related]
9. Persistent negative symptoms in youth at clinical high risk for psychosis: A longitudinal study.
Devoe DJ; Lu L; Cannon TD; Cadenhead KS; Cornblatt BA; McGlashan TH; Perkins DO; Seidman LJ; Tsuang MT; Woods SW; Walker EF; Mathalon DH; Bearden CE; Addington J
Schizophr Res; 2021 Jan; 227():28-37. PubMed ID: 32362460
[TBL] [Abstract][Full Text] [Related]
10. Evaluating the Social Functioning Scale modified for use in individuals at clinical high-risk for psychosis.
Kuhney FS; Damme KSF; Ellman LM; Schiffman J; Mittal VA
Schizophr Res; 2022 Oct; 248():246-253. PubMed ID: 36115189
[TBL] [Abstract][Full Text] [Related]
11. The impact of early factors on persistent negative symptoms in youth at clinical high risk for psychosis.
Devoe DJ; Lui L; Cannon TD; Cadenhead KS; Cornblatt BA; Keshavan M; McGlashan TH; Perkins DO; Seidman LJ; Stone WS; Tsuang MT; Woods SW; Walker EF; Mathalon DH; Bearden CE; Addington J
Front Psychiatry; 2023; 14():1125168. PubMed ID: 37293402
[TBL] [Abstract][Full Text] [Related]
12. Sampling from different populations: Sociodemographic, clinical, and functional differences between samples of first episode psychosis individuals and clinical high-risk individuals who progressed to psychosis.
Hagler MA; Ferrara M; Yoviene Sykes LA; Li F; Addington J; Bearden CE; Cadenhead KS; Cannon TD; Cornblatt BA; Perkins DO; Mathalon DH; Seidman LJ; Tsuang MT; Walker EF; Powers AR; Allen AR; Srihari VH; Woods SW
Schizophr Res; 2023 May; 255():239-245. PubMed ID: 37028205
[TBL] [Abstract][Full Text] [Related]
13. Meta-analytic prevalence of comorbid mental disorders in individuals at clinical high risk of psychosis: the case for transdiagnostic assessment.
Solmi M; Soardo L; Kaur S; Azis M; Cabras A; Censori M; Fausti L; Besana F; Salazar de Pablo G; Fusar-Poli P
Mol Psychiatry; 2023 Jun; 28(6):2291-2300. PubMed ID: 37296309
[TBL] [Abstract][Full Text] [Related]
14. Dynamic Prediction of Outcomes for Youth at Clinical High Risk for Psychosis: A Joint Modeling Approach.
Worthington MA; Addington J; Bearden CE; Cadenhead KS; Cornblatt BA; Keshavan M; Lympus CA; Mathalon DH; Perkins DO; Stone WS; Walker EF; Woods SW; Zhao Y; Cannon TD
JAMA Psychiatry; 2023 Oct; 80(10):1017-1025. PubMed ID: 37531131
[TBL] [Abstract][Full Text] [Related]
15. Predictors of a clinical high risk status among individuals with a family history of psychosis.
Stowkowy J; Addington J
Schizophr Res; 2013 Jul; 147(2-3):281-6. PubMed ID: 23611242
[TBL] [Abstract][Full Text] [Related]
16. White matter changes in psychosis risk relate to development and are not impacted by the transition to psychosis.
Di Biase MA; Cetin-Karayumak S; Lyall AE; Zalesky A; Cho KIK; Zhang F; Kubicki M; Rathi Y; Lyons MG; Bouix S; Billah T; Anticevic A; Schleifer C; Adkinson BD; Ji JL; Tamayo Z; Addington J; Bearden CE; Cornblatt BA; Keshavan MS; Mathalon DH; McGlashan TH; Perkins DO; Cadenhead KS; Tsuang MT; Woods SW; Stone WS; Shenton ME; Cannon TD; Pasternak O
Mol Psychiatry; 2021 Nov; 26(11):6833-6844. PubMed ID: 34024906
[TBL] [Abstract][Full Text] [Related]
17. Comorbid Mental Disorders and 6-Month Symptomatic and Functioning Outcomes in Chinese University Students at Clinical High Risk for Psychosis.
Shi J; Wang L; Yao Y; Su N; Zhan C; Mao Z; Zhao X
Front Psychiatry; 2017; 8():209. PubMed ID: 29109690
[TBL] [Abstract][Full Text] [Related]
18. Baseline antipsychotic prescription and short-term outcome indicators in individuals at clinical high-risk for psychosis: Findings from the Parma At-Risk Mental States (PARMS) program.
Pelizza L; Leuci E; Quattrone E; Azzali S; Paulillo G; Pupo S; Poletti M; Raballo A; Pellegrini P; Menchetti M
Early Interv Psychiatry; 2024 Feb; 18(2):71-81. PubMed ID: 37194411
[TBL] [Abstract][Full Text] [Related]
19. Obsessive-Compulsive Spectrum Symptoms Are Associated With Functional Impairment in Children and Adolescents With Psychosis Risk Syndrome: The CAPRIS Study.
Vergara L; de la Serna E; Sugranyes G; Puig O; Ilzarbe D; Fortea A; Tor J; Muñoz-Samons D; Rodriguez-Pascual M; Alvarez-Subiela J; Dolz M; Baeza I
J Clin Psychiatry; 2023 Oct; 84(6):. PubMed ID: 37870364
[No Abstract] [Full Text] [Related]
20. The characteristics and clinical outcomes of a pluripotent high-risk group with the potential to develop a diverse range of psychiatric disorders.
Lee TY; Lee H; Lee J; Lee Y; Rhee SJ; Park DY; Paek MJ; Kim EY; Kim E; Roh S; Jung HY; Kim M; Kim SH; Ahn YM; Ha K; Kwon JS
J Psychiatr Res; 2024 Jun; 174():237-244. PubMed ID: 38653032
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
